Publications (Val Runge)
1. Rand TH, Clanton JA, Runge V, English D, Colley DG. Murine eosinophils labeled with Indium-111 oxine: Localization to delayed hypersensitivity reactions against a schistosomal antigen and to lymphokine in vivo. Blood 1983; 61(4):732-739.
2. Runge VM, Rand TH, Clanton JA, Jones JP, Colley DG, Partain CL, James AE. Work in progress: radionuclide imaging of indium-111-labeled eosinophils in mice. Radiology 1983 147:563-565.
3. Runge VM, Stewart RG, Clanton JA, Jones MM, Lukehart CM, Partain CL, James AE. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 1983; 147:789-791.
4. Runge VM, Clanton JA, Smith FW, Hutchison J, Mallard J, Partain CL, James AE. Nuclear magnetic resonance of iron and copper disease states. American Journal of Roentgenology 1983; 141:943-948.
5. Runge VM, Clanton JA, Lukehart CM, Partain CL, James AE. Paramagnetic agents for contrast-enhanced NMR imaging: a review. American Journal of Roentgenology 1983; 141:1209-1215.
6. Runge VM, Clanton JA, Partain CL, James AE. Respiratory gating in magnetic resonance imaging at 0.5 tesla. Radiology 1984; 151:521-523.
7. Stewart RG, Runge VM, Brenner DE, Witt WS, Partain CL, James AE. Nuclear magnetic resonance relaxation rates of serum from lung cancer patients: work in progress. J Tenn Med Assoc 1984; 77(3):131-133.
8. Runge VM, Foster MA, Clanton JA, Jones MM, Lukehart CM, Hutchison JMS, Mallard JR, Smith FW, Partain CL, James AE. Contrast enhancement of magnetic resonance imaging by chromium EDTA: an experimental study. Radiology 1984; 152:123-126.
9. Runge VM, Clanton JA, Herzer WA, Gibbs SJ, Price AC, Partain CL, James AE. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 1984; 153:171-176.
10. Runge VM, Price AC, Kirshner HS, Allen JH, Partain CL, James AE. Magnetic resonance imaging of multiple sclerosis: a study of pulse-technique efficacy. American Journal of Roentgenology 1984; 143:1015-1026.
11. Runge VM, Clanton JA, Price AC, Herzer WA, Wehr CJ, Lukehart CM, Partain CL, James AE. Paramagnetic contrast agents in magnetic resonance imaging: research at Vanderbilt University. Physiol Chem Physics Med NMR 1984; 16:113-122.
12. Runge VM, Clanton JA, Foster MA, Smith FW, Lukehart CM, Jones MM, Partain CL, James AE. Paramagnetic NMR contrast agents: development and evaluation. Investigative Radiology 1984 19:408-415.
13. Smith FW, Runge V, Permezel M, Smith CC. Nuclear magnetic resonance imaging in the diagnosis of spinal osteomyelitis. Magnetic Resonance Imaging 1984; 2(1):53-56.
14. Runge VM, Clanton JA, Price AC, Herzer WA, Allen JH, Partain CL, James AE. Dyke Award. Evaluation of contrast enhanced MR imaging in a brain abscess model. American Journal of Neuroradiology 1985; 6:139-147.
15. James AE Jr., Partain CL, Patton JA, Mitchell MR, Clanton JA, Runge VM, Price AC, Kulkarni MV, Price RR. Current status of magnetic resonance imaging. South Med J 1985;78(5):580-97.
16. Runge VM, Schoerner V, Niendorf HP, Laniado M, Koehler D, Claussen C, Felix R, James AE. Initial clinical evaluation of gadolinium DTPA for contrast enhanced magnetic resonance imaging. Magnetic Resonance Imaging 1985; 3(1):27-35.
17. Runge VM, Clanton JA, Price AC, Wehr CJ, Herzer WA, Partain CL, James AE. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magnetic Resonance Imaging 1985; 3(1):43-55.
18. Runge VM, Foster MA, Clanton JA, Smith FW, Lukehart CM, Hutchison JMS, Mallard JR, Partain CL, James AE. Particulate oral NMR contrast agents. International Journal of Nuclear Medicine and Biology 1985; 12(1):37-42.
19. Kirshner HS, Tsai SI, Runge VM, Price AC. Magnetic resonance imaging and other techniques in the diagnosis of multiple sclerosis. Archives of Neurology 1985; 42(9):859-863.
20. Runge VM, Rand TH, Clanton JA, Jones JP, Colley DG, Partain CL, James AE. Indium-111-labeled eosinophils: Localization of inflammatory lesions and parasitic infections in mice. International Journal Nuclear Medicine and Biology 1985; 12(2):135-144.
21. Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF. Contrast enhanced MRI: evaluation of a canine model of osmotic blood-brain barrier disruption. Investigative Radiology 1985; 20(6):830-844.
22. Runge VM, Clanton JA, Wehr CJ, Partain CL, James AE. Gated magnetic resonance imaging of acute myocardial ischemia in dogs: application of multiecho techniques and contrast enhancement with Gd DTPA. Magnetic Resonance Imaging 1985; 3:255-266.
23. Price AC, Runge VM, Allen JH, Partain CL, James AE. Primary glioma: Diagnosis with magnetic resonance imaging. CT: The Journal of Computed Tomography 1986; 10:325-334.
24. Wolpert SM, Scott RM, Runge VM, Kwan ES. Difficulties in diagnosing congenital posterior fossa fluid collections after shunting procedures. American Journal of Neuroradiology 1987; 8:653-656.
25. Wolpert SM, Anderson M, Scott MR, Kwan ESK, Runge VM. Chiari II malformation: MR imaging evaluation. American Journal of Neuroradiology 1987; 8:783-790.
26. Runge VM, Price AC, Kirshner HS, Allen JH, Partain CL, James AE. The evaluation of multiple sclerosis by magnetic resonance imaging. Radiographics 1986; 6(2):203-210.
27. Runge VM, Osborne MA, Wood ML, Wolpert SM, Kwan E, Kaufman DM. The efficacy of tilted axial MRI of the CNS. Magnetic Resonance Imaging 1987; 5(6):421-430.
28. Wood ML, Silver M, Runge VM. Optimization of spoiler gradients in FLASH MRI. Magnetic Resonance Imaging 1987; 5:455-463.
29. Runge VM, Jacobson S, Wood ML, Kaufman DM, Adelman LS. MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA. Radiology 1988; 166(3):835-838.
30. Wood ML, Runge VM, Henkelman RM. Overcoming motion in abdominal MR imaging. American Journal of Roentgenology 1988; 150:513-522.
31. Wolpert SM, Osborne M, Anderson M, Runge VM. The bright pituitary gland -- a normal MR appearance in infancy. American Journal of Neuroradiology 1988; 9(1):1-3.
32. Runge VM. Gd-DTPA: An i.v. contrast agent for clinical MRI. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology 1988; 15(1):37-44.
33. Runge VM, Schaible TF, Goldstein HA, Wood ML, Haughton VM, Maravilla KR, Weinstein MA, Price AC, Wolpert SM, Kaufman DM. Gd DTPA - clinical efficacy. Radiographics 1988; 8(1):147-159.
34. Runge VM, Wood ML, Kaufman DM, Price AC. Gd DTPA. Future applications with advanced imaging techniques. Radiographics 1988; 8(1):161-179.
35. Runge VM, Wood ML, Kaufman DM, Silver MS. MR imaging section profile optimization: improved contrast and detection of lesions. Radiology 1988; 167:831-834.
36. Runge VM, Wood ML, Kaufman DM, Traill MR, Nelson KL. The straight and narrow path to good head and spine MRI. Radiographics 1988; 8(3):507-531.
37. Kwan ES, Wolpert SM, Scott RM, Runge V. MR evaluation of neurovascular lesions after endovascular occlusion with detachable balloons. American Journal of Neuroradiology 1988; 9(3):523-531.
38. Davis PL, Parker DL, Nelson JA, Gillen JS, Runge VM. Interactions of paramagnetic contrast agents and the spin echo pulse sequence. Investigative Radiology 1988; 23(5):381-388.
39. Wood ML, Runge VM. Application of image enhancement techniques to magnetic resonance imaging. Radiographics 1988; 8(4):771-784.
40. Carter BL, Runge VM: Imaging modalities for the study of the paranasal sinuses and nasopharynx. Otolaryngologic Clinics of North America. GE Valvassori and MF Mafee (Editors), W.B. Saunders, Philadelphia, 1988; 21(3):395-420.
41. Konstam MA, Aronovitz MJ, Runge VM, Kaufman DM, Brockway BA, Isner JM, Katzen NA, Dresdale AR, Diehl JT, Kaplan E, et al. Magnetic resonance imaging with gadolinium-DTPA for detecting cardiac transplant rejection in rats. Circulation 1988; 78(5):III-87-94.
42. Wolpert SM, Scott RM, Platenberg RC, Runge VM. The clinical significance of hindbrain herniation and deformity as shown on MR images of patients with Chiari II malformation. American Journal of Neuroradiology 1988; 9(1):1075-1078.
43. Canoso JJ, Liu N, Traill MR, Runge VM. Physiology of the retrocalcaneal bursa. Ann Rheum Dis 1988; 47(11):910-2.
44. Runge VM, Wood ML. Fast imaging and other motion artifact reduction schemes: a pictorial overview. Magnetic Resonance Imaging 1988; 6(5):595-608.
45. Runge VM, Wood ML, Kaufman DM, Nelson KL, Traill MR. FLASH: clinical three-dimensional magnetic resonance imaging. Radiographics 1988; 8(5):947-965.
46. Wood ML, Runge VM. Artifacts due to residual magnetization in three-dimensional magnetic resonance imaging. Medical Physics 1988; 15(6):825-831.
47. Robertson SW, Wolpert SM, Runge VM. Magnetic resonance imaging of middle cranial fossa arachnoid cysts: temporal lobe agenesis syndrome revisited. American Journal of Neuroradiology 1989; 10:1007-1010.
48. Runge VM, Carollo BR, Wolf CR, Nelson KL, Gelblum DY. Gd DTPA: a review of clinical indications in the central nervous system magnetic resonance imaging. Radiographics 1989; 9(5): 929-958.
49. Runge VM, Kaufman DM, Wood ML, Adelman LS, Jacobson S. Experimental trials with Gd(DO3A) -- a nonionic magnetic resonance contrast agent. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology 1989; 16(6):561-567.
50. Runge VM, Wood ML. Half-fourier MR imaging of CNS disease. American Journal of Neuroradiology 1990; 11:77-82.
51. Traill MR, Kaufman DM, Runge VM, McCarthy JC, Wood ML, Sterns DM, Harasimowicz PP. Anatomy of the proximal femur as seen with three-dimensional magnetic resonance imaging. J Arthroplasty 1989; 4(4):361-7.
52. Runge VM, Gelblum DY. The role of gadolinium-diethylenetriaminepentaacetic acid in evaluation of the central nervous system. Magnetic Resonance Quarterly 1990; 6(2):85-107.
53. Carollo BR, Runge VM, Price AC, Nelson KL, Wolf CR, Pacetti MI. The prospective evaluation of Gd DTPA in 225 consecutive cranial cases: adverse reactions and diagnostic value. Magnetic Resonance Imaging 1990; 8:381-393.
54. Runge VM, Gelblum DY, Pacetti ML, Carolan F, Heard G. Gd HP-DO3A in clinical MR imaging of the brain. Radiology 1990; 177:393-400.
55. Runge VM, Gelblum DY, Wood ML. 3-D imaging of the CNS. Neuroradiology 1990; 32:356-366.
56. Runge VM. Clinical applications of magnetic resonance contrast media in the head. Topics in Magnetic Resonance Imaging 1991; 3(2):19-40.
57. Runge VM, Gelblum DY. Future directions in magnetic resonance contrast media. Topics in Magnetic Resonance Imaging 1991; 3(2):85-98.
58. Runge VR, Gelblum DY, Jacobson S. Gd HP-DO3A -- experimental evaluation in brain and renal MR. Magnetic Resonance Imaging 1991; 9(1):79-87.
59. Runge VM, Bradley WG, Brant-Zawadzki MN, Carvlin MJ, DeSimone DN, Dean BL, Dillon WP, Drayer BP, Flanders AE, Harms SE, et al. Clinical safety and efficacy of gadoteridol: a study of 411 patients with suspected intracranial and spinal disease. Radiology 1991; 181:701-709.
60. Konstam MA, Aronovitz MJ, Runge VM, Isner JM, Foster EA, Kaufman DM, Diehl JT, Dresdale AR, Katzen NA, Kaplan E. Magnetic resonance imaging in ischemic injury after heart transplantation in rats. Journal of Heart and Lung Transplantation 1991; 10:750-756.
61. Runge VM. Magnetic resonance imaging contrast agents [editorial]. Current Opinion in Radiology 1992; 4(1):3-12.
62. Runge VM, Kirsch JE, Thomas GS, Mugler JP. Clinical comparison of three-dimensional MP-RAGE and FLASH techniques for MR imaging of the head. Journal of Magnetic Resonance Imaging 1991; 1(4):493-500.
63. Shih WJ, Hartman RS, McQuaide BH, Nugent E, Runge VM, Ryo UY. A large cystic lesion in the left posterior parietal region demonstrated by Tc-99m HMPAO brain SPECT imaging. Clin Nucl Med 1992; 17(1):54-55.
64. Runge VM, Dean B, Lee C, Carolan F, Heard G. Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. Journal of Magnetic Resonance Imaging 1991; 1:47-56.
65. Runge VM, Kirsch JE, Thomas GS. High dose applications of gadolinium chelates in magnetic resonance imaging. Magnetic Resonance in Medicine 1991; 22:358-363.
66. Lee C, Dean BL, Kirsch JE, Runge VM, Dempsey RJ, Howard RS, Pettigrew LC. Cerebral infarction: assessment of patterns using ultra-fast MR contrast imaging. American Journal of Neuroradiology 1992; 13:277-279.
67. Dean BL, Lee C, Kirsch JE, Runge VM, Dempsey RM, Pettigrew LC. Cerebral hemodynamics and cerebral blood volume: MR assessment using gadolinium contrast agents and T1-weighted turbo-FLASH imaging. American Journal of Neuroradiology 1992; 13:39-48.
68. Runge VM, Kirsch JE, Burke VJ, Price AC, Nelson KL, Thomas GS, Dean BL, Lee C. High-dose gadoteridol in MR imaging of intracranial neoplasms. Journal of Magnetic Resonance Imaging 1992; 2:9-18.
69. Runge VM, Bronen R, Davis KR. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine. Investigative Radiology 1992; 27(1):S22-S32.
70. Kaye EM, Alroy J, Raghavan SS, Schwarting GA, Adelman LS, Runge V, Gelblum D, Thalhammer JG, Zuniga G. Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatric Neurology 1992;8(4):255-261.
71. Runge VM, Kirsch JE, Lee C. Contrast-enhanced MR angiography. Journal of Magnetic Resonance Imaging 1993;3:233-239.
72. Runge VM, Kirsch JE, Wells JW, Woolfolk CE. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study. American Journal of Roentgenology 1993;160:593-600.
73. Hudgins PA, Elster AD, Runge VM, Kashanian FK, Goldstein HA. Efficacy and safety of gadopentetate dimeglumine in the evaluation of patients with a suspected tumor of the extracranial head and neck. Journal of Magnetic Resonance Imaging 1993;3:345-349.
74. Lee C, Dineen TE, Brack M, Kirsch JE, Runge VM. The mucopolysaccharidoses: characterization by cranial MR imaging. American Journal of Neuroradiology 1993;14:1285-1292.
75. Runge VM, Kirsch JE, Wells JW, Awh MH, Bittner DF, Woolfolk CE. Enhanced liver MR: contrast agents and imaging strategy. Critical Reviews in Diagnostic Imaging 1993;34:1-30.
76. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material. American Journal of Roentgenology 1994;162:431-435.
77. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Awh MH, Bittner DF. Magnetic resonance contrast agents in neuroimaging: new agents and applications. Neuroimaging Clinics of North America 1994;4(1):175-183.
78. Yuh WTC, Nguyen HD, Tali ET, Mayr NA, Fisher DJ, Atlas SW, Carvlin MC, Drayer BP, Pollei SR, Runge VM, Sze GK. Delineation of gliomas with various doses of MR contrast material. American Journal of Neuroradiology 1994;15:983-989.
79. Runge VM, Pels Rijcken TH, Davidoff A, Wells JW, Stark DD. Contrast-enhanced MR imaging of the liver. Journal of Magnetic Resonance Imaging 1994;4:281-289.
80. Runge VM, Kirsch JE, Woolfolk C, Brack MA, Garneau RA. Gadoteridol dose dependence in MR imaging of a liver abscess model. Journal of Magnetic Resonance Imaging 1994;4:343-350.
81. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Hilaire L, Woolfolk CE. Repeat cerebral blood volume assessment with first-pass MR imaging. Journal of Magnetic Resonance Imaging 1994;4:457-461.
82. Yuh WTC, Fisher DJ, Runge VM, Atlas SW, Harms SE, Maravilla KR, Mayr NA, Mollman JE, Price AC. Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. American Journal of Neuroradiology 1994;15:1037-1051 (June).
83. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. The question of dose for gadolinium chelates in magnetic resonance imaging. Investigative Radiology 1994;29(S2):154-156 (June).
84. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. Journal of Magnetic Resonance Imaging 1994;4(5):669-673 (September).
85. Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WTC, Runge VM, Morris MR, McLachlan SJ, Lufkin RB. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994;192:709-715 (September).
86. Mitchell DG, Saini S, Weinreb J, De Lange EE, Runge VM, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard and triple dose gadoteridol enhanced MR imaging. Radiology 1994;193:49-57 (October).
87. Runge VM, Wells JW, Williams NM. MR imaging of an experimental model of intracranial metastatic disease -- a study of lesion detectability. Investigative Radiology 1994;29(12):1050-1056.
88. Runge VM, Wells JW, Williams NM. Comparison of Gd Cy2DOTA, a new hepatobiliary agent, and Gd HP-DO3A, an extracellular agent, in normal liver and metastatic disease. Investigative Radiology 1995;30:123-130.
89. Runge VM, Wells JW, Kirsch JE. Magnetization transfer and high dose contrast in early brain infection on MR. Investigative Radiology 1995;30:135-143.
90. Nelson KL, Runge VM. Basic principles of MR contrast. Topics in Magnetic Resonance Imaging 1995;7(3):124-136.
91. Muroff LR, Runge VM. The use of MR contrast in neoplastic disease of the brain. Topics in Magnetic Resonance Imaging 1995;7(3):137-157.
92. Runge VM. The use of MR contrast in non-neoplastic disease of the brain. Topics in Magnetic Resonance Imaging 1995;7(3):158-167.
93. Jinkins JR, Runge VM. The use of MR contrast agents in the evaluation of disease of the spine. Topics in Magnetic Resonance Imaging 1995;7(3):168-180.
94. Runge VM, Wells JW. Update: safety, new applications, new MR agents. Topics in Magnetic Resonance Imaging 1995;7(3):181-195.
95. Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA, Jacobs PM. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
96. Petersein J, Saini S, Mitchell DG, Davis PL, Johnson CD, Kuhlman JE, Parisky YR, Runge VM, et al. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. AJR Am J Roentgenol 1995 Nov;165(5):1157-61.
97. Runge VM, Wells JW, Williams NM, Lee C, Timoney JF, Young AB. Detectability of early brain meningitis on MR. Investigative Radiology 1995;30(8):484-495.
98. Runge VM, Wells JW, Williams NM. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging. Investigative Radiology 1996;31(1):11-16.
99. Runge VM. Investigative Radiology and the World Wide Web. Investigative Radiology 1996;31(4):183 (editorial).
100. Runge VM, Wells JW, Williams NM, Timoney JF, Lee C. The use of gadolinium BOPTA on magnetic resonance imaging in brain infection. Investigative Radiology 1996;31(5):294-299.
101. Runge VM, Wells JW. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with MRI at 1.5 tesla. Investigative Radiology 1996;31(7):395-400.
102. Runge VM, Wells JW. Comparison of MR hepatobiliary gadolinium chelates, including BOPTA, EOB-DTPA, Cy2DOTA and 2,5-BPA-DO3A. Academic Radiology 1996;3:S455-S457.
103. Runge VM, Wells JW, Williams NM. Early dynamic MR imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection. Investigative Radiology 1996;31(8):472-478.
104. Runge VM, Wells JW, Williams NM. Hepatic abscesses: magnetic resonance imaging findings using gadolinium BOPTA. Investigative Radiology 1996;31(12):781-788.
105. Runge VM, Muroff LR, Wells JW. Principles of contrast enhancement in the evaluation of brain diseases: an overview. Journal of Magnetic Resonance Imaging 1997;7:5-13.
106. Runge VM, Wells JW, Baldwin SA, Scheff SW, Blades DA. Evaluation of the temporal evolution of acute spinal cord injury. Investigative Radiology 1997;32(2):105-110.
107. Runge VM, Wells JW, Williams NM. Renal metastasis: detection and characterization on enhanced magnetic resonance imaging using an animal model. Investigative Radiology 1997;32(4):212-127.
108. Runge VM. Liver MRI with contrast enhancement. Critical Reviews in Diagnostic Imaging 1997;38(3):207-230.
109. Runge VM, Lee C, Williams NM. Detectability of small liver metastases with gadolinium BOPTA. Investigative Radiology 1997;32(9):557-565.
110. Runge VM, Lee C, Iten AL, Williams NM. Contrast enhanced magnetic resonance imaging in a spinal epidural tumor model. Investigative Radiology 1997;32(10):589-595.
111. Runge VM, Timoney JF, Williams NM. Magnetic resonance imaging of experimental pyelonephritis in rabbits. Investigative Radiology 1997;32(11):696-704.
112. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. European Radiology 1997;7(suppl 5):S243-S245.
113. Runge VM, Williams NM. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis. Investigative Radiology 1998;33(1):45-50.
114. Runge VM, Williams NM. Investigation of MR contrast media utility with the VX-2 tumor model. Academic Radiology 1998;5(suppl 1):S34-S36.
115. Runge VM, Williams NM, Lee C, Timoney JF. Magnetic resonance imaging in a spinal abscess model. Investigative Radiology 1998;33(4):246-255.
116. Runge VM. Evaluation of standard and high dose contrast enhanced breath-hold liver MR for visualization of metastatic disease in an animal model. Investigative Radiology 1998;33(5):263-267.
117. Runge VM. A comparison of two MR hepatobiliary gadolinium chelates, Gd-BOPTA and Gd-EOB-DTPA. Journal of Computer Assisted Tomography 1998;22(July/August):643-650.
118. Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK, Morris M, Lucas M. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. Journal of Magnetic Resonance Imaging 1999;9:291-294.
119. Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF,…, Runge VM, et al. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal of Magnetic Resonance Imaging 1999;10:15-24.
120. Runge VM, Knopp MV. Changes in the approval process for contrast media. Journal of Magnetic Resonance Imaging 1999;10(3):485-488.
121. Runge VM. Off-label use and reimbursement of contrast media in MR. Journal of Magnetic Resonance Imaging 1999;10(3):489-495.
122. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N. MR imaging of tumor microcirculation: promise for the new millennium. Journal of Magnetic Resonance Imaging 1999;10(6)903-7.
123. Runge VM. Contrast media research. Investigative Radiology 1999;34(12):785-90.
124. Marinelli ER, Neubeck R, Song B, Wagler T, Ranganathan RS, Sukumaran K Wedeking PW, Nunn A, Runge VM, Tweedle MF. Synthesis, characterization and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents. Investigative Radiology 2000;35(1):8-24.
125. Runge VM, Kenney CM. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging. Journal of Magnetic Resonance Imaging 2000; 11(6):655-64. Reprinted in Applied Radiology 2003; April (supplement): 137-146.
126. Runge VM. Safety of approved MR contrast media for intravenous injection. Journal of Magnetic Resonance Imaging 2000;12:205-213 (August).
127. Shih WJ, Runge VM, Mitchell BL, Pulmano C. Comparison of bone SPECT, MRI, and CT in the demonstration of vertebral metastases from bronchogenic carcinoma: an autopsy documented case. Clinical Nuclear Medicine August 2000; 25:647-9.
128. Saini S, Sharma R, Baron RL, Turner DA, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clinical Radiology 2000;55(9):690-5.
129. Runge VM, Armstrong MR, Barr RG, et al. A Clinical Comparison of the Safety and Efficacy of MultiHance (Gadobenate Dimeglumine) and Omniscan (Gadodiamide) in Magnetic Resonance Imaging in Patients with Central Nervous System Pathology. Investigative Radiology 2001;36(2):65-71. Reprinted in Applied Radiology 2003; April (supplement): 71-77.
130. Runge VM. A review of contrast media research in 1999 - 2000. Investigative Radiology 2001;36(2):123-130.
131. Knopp MV, Lodemann M, Kage U, Runge VM. Use of MR contrast agents outside of their labeled indication. Radiologe 2001;41:296-302.
132. Essig M, Hartmann M, Lodemann KP, et al. [Comparison of contrast behavior of gadobenate-dimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study]. Radiologe 2001;41:1063-1071. Reprinted in Applied Radiology 2003; April (supplement): 92-100.
133. Runge, VM. Allergic reactions to gadolinium chelates. American Journal of Roentgenology 2001;177:944 (letter to Editor).
134. Runge VM. Editorial. Topics in Magnetic Resonance Imaging 2001;12(4):219.
135. Runge VM, Muroff LR, Jinkins JR. Central Nervous System: Review of Clinical Use of Contrast Media. Topics in Magnetic Resonance Imaging 2001;12(4):231-263.
136. Runge VM. Safety of Magnetic Resonance Contrast Media. Topics in Magnetic Resonance Imaging 2001;12(4):309-314.
137. Runge VM. Trends in Contrast Media Research (Editorial). Investigative Radiology 2001;36(12):688-691.
138. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Investigative Radiology 2002;37(5):269-280.
139. Runge VM, Dickey KM, Williams NM, Peng X. Local Tissue Toxicity in Response to Extravascular Extravasation of Magnetic Resonance Contrast Media. Investigative Radiology 2002;37(7):393-8.
140. Marinelli ER, Neubeck R, Song B, Wagler T, Ranganathan RS, Sukumaran K Wedeking P, Nunn A, Runge VM, Tweedle MF. Synthesis and evaluation of macrocyclic gadolinium chelates as hepatospecific MRI agents. Academic Radiology 2002:9(supplement 1):251-4.
141. Runge VM. Contrast Media Research (Editorial). Investigative Radiology 2002;37(12):643-6.
142. Desai NK, Runge VM, Crisp DE, Crisp MB, Naul LG. Magnetic resonance imaging of the brain in glutaric acidemia type I: a review of the literature and a report of four new cases with attention to the basal ganglia and imaging technique. Investigative Radiology 2003:38(8):489-96.
143. Runge VM. Editorial. Topics in Magnetic Resonance Imaging 2003;14(5):359 (October).
144. Desai NK, Runge VM. Contrast Use at Low Field: a Review. Topics in Magnetic Resonance Imaging 2003;14(5):360-4 (October).
145. Kirchin MA, Runge VM. Contrast Agents for Magnetic Resonance Imaging: Safety Update. Topics in Magnetic Resonance Imaging 2003;14(5):426-35 (October).
146. Runge VM. Magnetic Resonance Research (Editorial). Investigative Radiology 2003;38(12):802-5.
147. Knopp MV, Runge VM, Essig M, et al. Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine. Radiology 2004;230:55-64.
148. Runge VM. Advances in Magnetic Resonance (Editorial). Investigative Radiology 2004;39(12):713-716.
149. Biswas J, Nelson B, Runge VM, Wintersperger BJ, Baumann SS, Jackson CB, Patel T. Brain Tumor Enhancement in MR Imaging: Comparison of Signal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) at 1.5 versus 3 Tesla. Investigative Radiology 2005;40(12):792-797.
150. Runge VM. Advances in Magnetic Resonance 2005 (Review). Investigative Radiology 2005;40(12):798-802.
151. Runge VM, Kuehl TJ, Jackson CB, Estrada EA. Subchronic Toxicity of the Gadolinium Chelates. Academic Radiology May 2005;12(Supplement 1):S6-9.
152. Runge VM, Case RS, Sonnier HL. Advances in Clinical 3-Tesla Neuroimaging. Investigative Radiology 2005;41(2):63-67.
153. Herborn CU, Watkins DM, Runge VM, Gendron JM, Montgomery ML, Naul LG. Renal arteries: comparison of steady-state free precession MR angiography and contrast-enhanced MR angiography. Radiology 2006;239:263-268.
154. Runge VM, Patel MC, Baumann SS, Simonetta AB, Ponzo JA, et al. T1-weighted Imaging of the Brain at 3 Tesla Using a 2D Spoiled Gradient Echo Technique. Investigative Radiology 2006;41(2):68-75.
155. Runge VM, Biswas J, Wintersperger BJ, Baumann SS, Jackson CB, Herborn CU, Patel T. The Efficacy of Gadobenate Dimeglumine (Gd-BOPTA) at 3 Tesla in Brain MR Imaging: Comparison to 1.5 Tesla and a Standard Gadolinium Chelate Using a Rat Brain Tumor Model. Investigative Radiology 2006;41(3):244-248.
156. Wintersperger BJ, Runge VM, Biswas J, Nelson CB, Stemmer A, Simonetta AB, Reiser MF, Naul LG, Schoenberg SS. Brain MR Imaging at 3 Tesla using BLADE Compared with Standard Rectilinear Data Sampling. Investigative Radiology 2006;41(7):586-592.
157. Nowinski WL, Qian G, Kirgaval Nagaraja BP, Thirunavuukarasuu A, Hu Q, Ivanov N, Parimal AS, Runge VM, Beauchamp NJ. Analysis of Ischemic Stroke MR Images by Means of Brain Atlases of Anatomy and Blood Supply Territories. Acad Radiol 2006;13:1025-1034.
158. Maravilla KR, Maldjian JA, Schmalfuss IM, Kuhn MJ, Bowen BC, Wippold FJ, Runge VM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389-400.
159. Kramer LA, Gendron JM, Pierce LM, Runge VM, Shull BL, Kuehl TJ. Magnetic resonance imaging of the levator ani in the squirrel monkey: A comparison of muscle volume between a cohort with pelvic organ prolapse and matched normals. Am J Obstet Gynecol 2006;194:1467-1471.
160. Runge VM. Advances in Magnetic Resonance (2006). Investigative Radiology 2006;41(12):904-9.
161. Wintersperger BJ, Sincleair S, Runge VM, Dietrich O, Huber A, Reiser MF, Schoenberg SO. Dual breath-hold magnetic resonance cine evaluation of global and regional cardiac function. European Radiology 2007;17(1):73-80.
162. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42(2):139-145
163. Kuhn MJ, Picozzi P, Maldjian JA, Schmalfuss IM, Maravilla KR, Bowen BC, Wippold FJ, Runge VM, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. Journal of Neurosurgery 2007;106:557-566.
164. Herborn CU, Watkins DM, Baumann S, Robert P, Corot C, Runge VM. Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T. Investigative Radiology 2007;42:622-628.
165. Runge VM. Advances in Magnetic Resonance (2007). Investigative Radiology 2007;42(12):862-7.
166. Herborn CU, Runge VM, Watkins DM, Gendron JM, Naul LG. MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T. AJR 2008; 190:173–177.
167. Runge VM. Notes on “Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent”. Centennial Article Commentary. American Journal of Roentgenology (AJR) 2008; 190:1433-1434.
168. Sandner TA, Houck P, Runge VM, Sincleair S, Huber AM, Theisen D, Reiser MF, Wintersperger BJ. Accuracy of accelerated cine MR imaging at 3 Tesla in longitudinal follow-up of cardiac function. Eur Radiol 2008;18(10):2095-101.
169. Fries P, Runge VM, Kirchin MA, Watkins DM, Buecker A, Schneider G. Magnetic Resonance Imaging of the Spine at 3 Tesla. Seminars in Musculoskeletal Radiology 2008;3(12):183-280.
170. Runge VM. Advances in Magnetic Resonance (2008). Investigative Radiology 2008;43(12):893-8.
171. Nowinski WL, Volkau I, Marchenko Y, Thirunavuukarasuu A, Ng TT, Runge VM. A 3D model of human cerebrovasculature derived from 3T magnetic resonance angiography. Neuroinformatics 2009;7:23-36.
172. Nowinski WL, Thirunavuukarasuu A, Volkau I, Marchenko Y, Aminah B, Gelas A, Huang S, Lee LC, Liu J, Ng TT, Nowinska NG, Qian GY, Puspitasari F, Runge VM. A new presentation and exploration of human cerebral vasculature correlated with surface and sectional neuroanatomy. Anat Sci Educ 2009;2(1):24-33.
173. Fries P, Runge VM, Buecker A, Schuerholz H, Reith W, Baumann SS, Robert P, Jackson C, Lanz T, Schneider G. Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla - Intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular Gd-Chelate in a rat brain tumor model. Invest Radiol 2009;44:200-206.
174. Wintersperger BJ, Runge VM, Tweedle MF, Jackson CB, Reiser MF. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol 2009;44:89-94.
175. Attenberger UI, Runge VM, Williams KD, Stemmer A, Michaely HJ, Reiser MF, Schoenberg SO, Wintersperger BJ. T1-weighted Brain Imaging with a 32-Channel Coil at 3T Using TurboFLASH BLADE Compared with Standard Cartesian k-Space Sampling. Invest Radiol 2009 44(3):177-183.
176. Runge, VM. Gadolinium and Nephrogenic Systemic Fibrosis. AJR Am J Roentgenol 2009 192:W195-196.
177. Attenberger UI, Runge VM, Jackson CB, Baumann S, Birkemeier K, Michaely HJ, Reiser MF, Schoenberg SO, Wintersperger BJ. Comparative Evaluation of Lesion Enhancement using 1 M Gadobutrol vs Two Conventional Gadolinium Chelates, all at a Dose of 0.1 mmol/kg, in a Rat Brain Tumor Model at 3 T. Invest Radiol 2009 44(5):251-6.
178. Fries P, Runge VM, Kirchin MA, Stemmer A, Naul LG, Williams KD, Buecker A, Schneider G. Diffusion Weighted Imaging in Patients with Acute Brain Ischemia at 3 T – Current Possibilities and Future Perspectives Comparing Conventional Echoplanar DWI and FSE DWI Sequences Using BLADE (PROPELLER). Invest Radiol 2009 44(6):351-9.
179. Attenberger UI, Runge VM, Stemmer A, et al. Diffusion Weighted Imaging: A Comprehensive Evaluation of a Fast Spin Echo DWI Sequence With BLADE (PROPELLER) k-Space Sampling at 3 T, Using a 32-Channel Head Coil in Acute Brain Ischemia. Invest Radiol 2009 44(10):656-661.
180. Runge VM. Advances in Magnetic Resonance (2009). Invest Radiol 2009 44(12):808–812.
181. Nowinski WL, Thirunavuukarasuu A, Volkau I, Marchenko Y, Aminah B, Puspitasari F, Runge, VM. A three-dimensional interactive atlas of cerebral arterial variants. Neuroinformatics 2009 7:255-264.
182. Morelli JN, Runge VM, Feiweier T, Kirsch JE, Williams KW, Attenberger UI. Evaluation of a Modified Stejskal-Tanner Diffusion Encoding Scheme, Permitting a Marked Reduction in TE, in Diffusion-Weighted Imaging of Stroke Patients at 3 T. Invest Radiol 2010 44(1):29-35.
183. Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ. Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine. AJR Am J Roentgenol 2010; 194:1337–1342.
184. Attenberger UI, Runge VM, Morelli JN, Williams J, Jackson C, Michaely HJ. Evaluation of Gadobutrol, a Macrocyclic, Non-ionic Gd Chelate in a Brain Glioma Model: Comparison with Gadoterate Meglumine and Gadopentetate Dimeglumine at 1.5 T, Combined with an Assessment of Field Strength Dependence, Specifically 1.5 vs 3 T. J Magn Reson Imaging 2010;31:549-555.
185. Giesel FL, Runge V, Kirchin M, et al. Three-dimensional multiphase time-resolved low-dose contrast-enhanced magnetic resonance angiography using TWIST on a 32-channel coil at 3 T: a quantitative and qualitative comparison of a conventional gadolinium chelate with a high-relaxivity agent. J Comput Assist Tomogr 2010;34:678-683.
186. Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI. Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T. Invest Radiol 2010 45(12):810-818.
187. Nowinski WL, Chua BC, Volkau I, Puspitasari R, Marchenko Y, Runge VM, Knopp MV. Simulation and assessment of cerebrovascular damage in deep brain stimulation using a stereotactic atlas of vasculature and structure derived from multiple 3- and 7-tesla scans. J Neurosurg 2010;113:1234-1241.
188. Runge VM. Advances in Diagnostic Radiology. Invest Radiol 2010 45(12):823-826.
189. Morelli JN, Runge VM, Williams JM, Beissner RS, Tweedle M. Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model. Invest Radiol 2011;46:169-177.
190. Kramer H, Runge VM, Morelli JN, et al. Magnetic resonance angiography of the carotid arteries: comparison of unenhanced and contrast enhanced techniques. Eur Radiol 2011 Aug;21(8):1667-76.
191. Bracken JN, Reyes M, Gendron JM, Pierce LM, Runge VM, Kuehl TJ. Alterations in pelvic floor muscles and pelvic organ support by pregnancy and vaginal delivery in squirrel monkeys. Int Urogynecol J 2011; 22:1109-1116.
192. Morelli JN, Runge VM, Ai F, et al. An image-based approach to understanding the physics of MR artifacts. Radiographics 2011 May-Jun;31(3):849-66.
193. Runge VM, Ai T, Hao D, Hu X. The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance. Invest Radiol 2011; 46:807–816.
194. Ai T, Padua A, Goerner F, Nittka M, Gugala Z, Jadhav S, Trelles M, Johnson RF, Lindsey RW, Li X, Runge VM. SEMAC-VAT and MSVAT-SPACE Sequence Strategies for Metal Artifact Reduction in 1.5 T Magnetic Resonance Imaging. Invest Radiol 2012;47:267-76.
195. Morelli JN, Runge VM, Ai F, et al. Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography. Invest Radiol 2012; 47:376-82.
196. Morelli JN, Ai F, Runge VM, et al. Time-resolved MR angiography of renal artery stenosis in a swine model at 3 Tesla using gadobutrol with digital subtraction angiography correlation. J Magn Reson Imaging 2012; 36(3):704-713.
197. Wuesten O, Morelli JN, Miller MW, Tuzun E, Lenox MW, Fossum TW, Trelles M, Cotes C, Krombach GA, Runge VM. MR angiography of carotid artery aneurysms in a porcine model at 3 tesla: Comparison of two different macrocyclic gadolinium chelates and of dynamic and conventional techniques. J Magn Reson Imaging 2012; 36(5):1203-12.
198. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012; 36(5):1060-71.
199. Ai T, Morelli JN, Hu X, Hao D, Goerner FL, Ager B, Runge VM. A Historical Overview of Magnetic Resonance Imaging, Focusing on Technological Innovations. Invest Radiol 2012;47:725-741.
200. Ai T, Goerner FL, Patel N, Trelles M, Wu G, Li X, Runge VM. Contrast Dose, Temporal Footprint, and Spatial Resolution Tradeoffs in Dynamic Contrast Enhanced MRA Performed in a Porcine Model of a Carotid Aneurysm. J Comput Assist Tomogr 2013;37(1):105-10.
201. Reichert M, Morelli JN, Runge VM, et al. Contrast-enhanced 3-dimensional SPACE versus MP-RAGE for the detection of brain metastases: considerations with a 32-channel head coil. Invest Radiol 2013;48(1):55-60.
202. Morelli JN, Gerdes CM, Schmitt P, Ai T, Saettele MR, Runge VM, et al. Technical considerations in MR angiography: an image-based guide. J Magn Reson Imaging 2013;37(6):1326-41.
203. Morelli J, Porter D, Ai F, Gerdes C, Saettele M, Feiweier T, et al. Clinical evaluation of single-shot and readout-segmented diffusion-weighted imaging in stroke patients at 3 T. Acta Radiol 2013;54(3):299-306.
204. Runge VM. Current technological advances in magnetic resonance with critical impact for clinical diagnosis and therapy. Invest Radiol 2013;48(12):869-77.
205. Finkenstaedt T, Morsbach F, Calcagni M, Vich M, Pfirrmann CW, Alkadhi H, Runge VM, Andreisek G, Guggenberger R. Metallic artifacts from internal scaphoid fracture fixation screws: comparison between C-arm flat-panel, cone-beam, and multidetector computed tomography. Invest Radiol 2014;49(8):532-9.
206. Goetschi S, Froehlich JM, Chuck NC, Curcio R, Runge VM, Andreisek G, et al. The protein and contrast agent-specific influence of pathological plasma-protein concentration levels on contrast-enhanced magnetic resonance imaging. Invest Radiol 2014;49(9):608-19.
207. Ai T, Yu K, Gao L, Zhang P, Goerner F, Runge VM, Li X. Diffusion tensor imaging in evaluation of thigh muscles in patients with polymyositis and dermatomyositis. Br J Radiol 2014;87(1043):20140261.
208. Daubler BF, Kamli A, Runge VM. Readout-Segmented Diffusion-Weighted Imaging in a Critical Anatomic Area - Diagnosing Posterior Ischemic Optic Neuropathy (PION). Rofo 2014;186(12):1151-2.
209. Zhang P, Yu K, Guo R, Shah S, Morelli JN, Runge VM, Li X. Ankylosing spondylitis: correlations between clinical and MRI indices of sacroiliitis activity. Clin Radiol 2015;70(1):62-6.
210. Runge VM, Paulo MMH, Andreisek G, Valavanis A, Alkadhi H. Recent Technological Advances in CT, and the Clinical Impact Therein. Invest Radiol 2015;50(2):119-27.
211. Shen Y, Goerner FL, Snyder C, Morelli JN, Hao D, Hu D, Li X, Runge VM. T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3 and 7 Tesla. Invest Radiol 2015;50(5):330-8.
212. Reichert M, Ai T, Morelli J, Nittka M, Attenberger U, Runge VM. Metal Artifact Reduction in MR Imaging at Both 1.5T and 3T Using Slice-Encoding for Metal Artifact Correction and View-Angle Tilting. BJR 2015;88(1048):20140601.
213. Filli L, Piccirelli M, Kenkel D, Guggenberger R, Andreisek G, Beck T, Runge VM, Boss A. Simultaneous Multislice Echo Planar Imaging With Blipped Controlled Aliasing in Parallel Imaging Results in Higher Acceleration: A Promising Technique for Accelerated Diffusion Tensor Imaging of Skeletal Muscle. Invest Radiol 2015;50(7):456-63.
214. Runge VM. Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. Invest Radiol 2015;50(8):481-2.
215. Runge VM. Fifty Years of the Best of Investigative Radiology. Invest Radiol 2015;50(9):549-50.
216. Runge VM, Aoki S, Bradley WG, Chang KH, Essig M, Ma L, Ross JS, Valavanis A. MRI and CT of the Brain, 50 Years of Innovation, With a Focus on the Future. Invest Radiol 2015;50(9):551-6.
217. Runge VM. Macrocyclic Versus Linear Gadolinium Chelates. Invest Radiol 2015;50(12):811.
218. Higashigaito K, Angst F, Runge VM, Alkadhi H, Donati OF. Metal Artifact Reduction in Pelvic Computed Tomography With Hip Prostheses: Comparison of Virtual Monoenergetic Extrapolations From Dual-Energy Computed Tomography and an Iterative Metal Artifact Reduction Algorithm in a Phantom Study. Invest Radiol. 2015;50(12):828-34.
219. Filli L, Piccirelli M, Kenkel D, Boss A, Manoliu A, Andreisek G, Bhat H, Runge VM, Guggenberger R. Accelerated magnetic resonance diffusion tensor imaging of the median nerve using simultaneous multi-slice echo planar imaging with blipped CAIPIRINHA. Eur Radiol. 2016;26(6):1921-8.
220. Filli L, Ghafoor S, Kenkel D, Liu W, Weiland E, Andreisek G, Frauenfelder T, Runge VM, Boss A. Simultaneous multi-slice readout-segmented echo planar imaging for accelerated diffusion-weighted imaging of the breast. Eur J Radiol. 2016;85(1):274-8.
221. Kenkel D, Wurnig MC, Filli L, Ulbrich E, Runge VM, et al. Whole-Body Diffusion Imaging Applying Simultaneous Multi-Slice Excitation. Rofo. 2016;188(4):381-8.
222. Runge VM. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus. Invest Radiol. 2016;51(5):273-9.
223. Zhang P, Yu KH, Guo RM, Ran J, Liu Y, Morelli J, Runge V, Li X. Comparing the diagnostic utility of sacroiliac spectral CT and MRI in axial spondyloarthritis. Br J Radiol. 2016;89(1059):20150196.
224. Zhang P, Yu KH, Guo RM, Ran J, Liu Y, Morelli J, Runge V, Li X. A novel diagnostic method (spectral computed tomography of sacroiliac joints) for axial spondyloarthritis. J Formos Med Assoc. 2016;115(8):658-64.
225. Schawkat K, Kuhn W, Inderbitzin D, Gloor B, Heverhagen JT, Runge VM, Christe A. Diagnostic Value and Interreader Agreement of the Pancreaticolienal Gap in Pancreatic Cancer on MDCT. PLoS One. 2016;11(11): e0166003.
226. Runge VM, Richter JK, Heverhagen JT. Speed in clinical magnetic resonance. Invest Radiol. 2017;52(1):1-17.
227. Runge VM. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Invest Radiol. 2017;52(6):317-23.
228. Filli L, Jud L, Luechinger R, Nanz D, Andreisek G, Runge VM, Kozerke S, Farshad-Amacker NA. Material-Dependent Implant Artifact Reduction Using SEMAC-VAT and MAVRIC - A Prospective MRI Phantom Study. Invest Radiol. 2017;52(6):381-7.
229. Schawkat K, Ith M, Christe A, Kuhn W, Chittazhathu Y, Bains L, Runge VM, Heverhagen JT. Dynamic non-invasive ASL perfusion imaging of a normal pancreas with secretin augmented MR imaging. Eur Radiol. 2018;28(6):2389-96.
230. Runge VM, Heverhagen JT. Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance. Invest Radiol. 2018;53:381-389.
231. Shen Y, Goerner FL, Heverhagen JT, Snyder C, Hu D, Li X, Runge VM. In vitro T2 relaxivities of the Gd-based contrast agents (GBCAs) in human blood at 1.5 and 3T. Acta Radiologica (Epub Date 2018/09/13).
232. Runge VM. Dechelation - Consequences and Safety Concerns with the Linear Gadolinium Based MR Contrast Media, In View of Recent Health Care Rulings by the EMA (Europe), FDA (USA), and PMDA (Japan). Invest Radiol. 2018;53:571-8.
233. Runge VM, Richter JK, Heverhagen JT. Motion in MR - New Paradigms for Improved Clinical Diagnosis. Invest Radiol 2019;54:(Epub Date 2019/04/05).
234. Bower DV, Richter JK, von Tengg-Kobligk H, Heverhagen JT, Runge VM. Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases with Reduced Kinetic Stability of the Agent. Invest Radiol 2019;54:(in press).
235. Runge VM. The clinical safety of gadoteridol, representative of the macrocyclic class of gadolinium-based contrast agents. J Magn Reson Imaging 2019 - First published: 15 October 2019, https://doi.org/10.1002/jmri.26957, 2020;51:869-70.
236. Runge VM, Heverhagen JT. Advocating the Development of Next-Generation, Advanced-Design Low-Field Magnetic Resonance Systems. Invest Radiol 2020;55:747-753.
237. Runge VM, Heverhagen JT. Scientific Advances, Investigative Radiology 2020 (and Beyond). Invest Radiol 2021;56:271-273.
238. Runge VM, Heverhagen JT. The Clinical Utility of Magnetic Resonance Imaging According to Field Strength, Specifically Addressing the Breadth of Current State-of-the-Art Systems, Which Include 0.55 T, 1.5 T, 3 T, and 7 T. Invest Radiol 2022;57:1-12.
239. Fritz J, Runge VM. Scientific Advances and Technical Innovations in Musculoskeletal Radiology. Invest Radiol. 2023;58(1):1-2.
240. Alkadhi H, Runge V. The Future Arrived: Photon-Counting Detector CT. Invest Radiol. 2023;58(7):439-40.
241. Runge VM, Heverhagen JT. A New Era in Magnetic Resonance Contrast Media. Invest Radiol. 2024;59(2):105-7.
1. Rand TH, Clanton JA, Runge V, English D, Colley DG. Murine eosinophils labeled with Indium-111 oxine: Localization to delayed hypersensitivity reactions against a schistosomal antigen and to lymphokine in vivo. Blood 1983; 61(4):732-739.
2. Runge VM, Rand TH, Clanton JA, Jones JP, Colley DG, Partain CL, James AE. Work in progress: radionuclide imaging of indium-111-labeled eosinophils in mice. Radiology 1983 147:563-565.
3. Runge VM, Stewart RG, Clanton JA, Jones MM, Lukehart CM, Partain CL, James AE. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 1983; 147:789-791.
4. Runge VM, Clanton JA, Smith FW, Hutchison J, Mallard J, Partain CL, James AE. Nuclear magnetic resonance of iron and copper disease states. American Journal of Roentgenology 1983; 141:943-948.
5. Runge VM, Clanton JA, Lukehart CM, Partain CL, James AE. Paramagnetic agents for contrast-enhanced NMR imaging: a review. American Journal of Roentgenology 1983; 141:1209-1215.
6. Runge VM, Clanton JA, Partain CL, James AE. Respiratory gating in magnetic resonance imaging at 0.5 tesla. Radiology 1984; 151:521-523.
7. Stewart RG, Runge VM, Brenner DE, Witt WS, Partain CL, James AE. Nuclear magnetic resonance relaxation rates of serum from lung cancer patients: work in progress. J Tenn Med Assoc 1984; 77(3):131-133.
8. Runge VM, Foster MA, Clanton JA, Jones MM, Lukehart CM, Hutchison JMS, Mallard JR, Smith FW, Partain CL, James AE. Contrast enhancement of magnetic resonance imaging by chromium EDTA: an experimental study. Radiology 1984; 152:123-126.
9. Runge VM, Clanton JA, Herzer WA, Gibbs SJ, Price AC, Partain CL, James AE. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 1984; 153:171-176.
10. Runge VM, Price AC, Kirshner HS, Allen JH, Partain CL, James AE. Magnetic resonance imaging of multiple sclerosis: a study of pulse-technique efficacy. American Journal of Roentgenology 1984; 143:1015-1026.
11. Runge VM, Clanton JA, Price AC, Herzer WA, Wehr CJ, Lukehart CM, Partain CL, James AE. Paramagnetic contrast agents in magnetic resonance imaging: research at Vanderbilt University. Physiol Chem Physics Med NMR 1984; 16:113-122.
12. Runge VM, Clanton JA, Foster MA, Smith FW, Lukehart CM, Jones MM, Partain CL, James AE. Paramagnetic NMR contrast agents: development and evaluation. Investigative Radiology 1984 19:408-415.
13. Smith FW, Runge V, Permezel M, Smith CC. Nuclear magnetic resonance imaging in the diagnosis of spinal osteomyelitis. Magnetic Resonance Imaging 1984; 2(1):53-56.
14. Runge VM, Clanton JA, Price AC, Herzer WA, Allen JH, Partain CL, James AE. Dyke Award. Evaluation of contrast enhanced MR imaging in a brain abscess model. American Journal of Neuroradiology 1985; 6:139-147.
15. James AE Jr., Partain CL, Patton JA, Mitchell MR, Clanton JA, Runge VM, Price AC, Kulkarni MV, Price RR. Current status of magnetic resonance imaging. South Med J 1985;78(5):580-97.
16. Runge VM, Schoerner V, Niendorf HP, Laniado M, Koehler D, Claussen C, Felix R, James AE. Initial clinical evaluation of gadolinium DTPA for contrast enhanced magnetic resonance imaging. Magnetic Resonance Imaging 1985; 3(1):27-35.
17. Runge VM, Clanton JA, Price AC, Wehr CJ, Herzer WA, Partain CL, James AE. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magnetic Resonance Imaging 1985; 3(1):43-55.
18. Runge VM, Foster MA, Clanton JA, Smith FW, Lukehart CM, Hutchison JMS, Mallard JR, Partain CL, James AE. Particulate oral NMR contrast agents. International Journal of Nuclear Medicine and Biology 1985; 12(1):37-42.
19. Kirshner HS, Tsai SI, Runge VM, Price AC. Magnetic resonance imaging and other techniques in the diagnosis of multiple sclerosis. Archives of Neurology 1985; 42(9):859-863.
20. Runge VM, Rand TH, Clanton JA, Jones JP, Colley DG, Partain CL, James AE. Indium-111-labeled eosinophils: Localization of inflammatory lesions and parasitic infections in mice. International Journal Nuclear Medicine and Biology 1985; 12(2):135-144.
21. Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF. Contrast enhanced MRI: evaluation of a canine model of osmotic blood-brain barrier disruption. Investigative Radiology 1985; 20(6):830-844.
22. Runge VM, Clanton JA, Wehr CJ, Partain CL, James AE. Gated magnetic resonance imaging of acute myocardial ischemia in dogs: application of multiecho techniques and contrast enhancement with Gd DTPA. Magnetic Resonance Imaging 1985; 3:255-266.
23. Price AC, Runge VM, Allen JH, Partain CL, James AE. Primary glioma: Diagnosis with magnetic resonance imaging. CT: The Journal of Computed Tomography 1986; 10:325-334.
24. Wolpert SM, Scott RM, Runge VM, Kwan ES. Difficulties in diagnosing congenital posterior fossa fluid collections after shunting procedures. American Journal of Neuroradiology 1987; 8:653-656.
25. Wolpert SM, Anderson M, Scott MR, Kwan ESK, Runge VM. Chiari II malformation: MR imaging evaluation. American Journal of Neuroradiology 1987; 8:783-790.
26. Runge VM, Price AC, Kirshner HS, Allen JH, Partain CL, James AE. The evaluation of multiple sclerosis by magnetic resonance imaging. Radiographics 1986; 6(2):203-210.
27. Runge VM, Osborne MA, Wood ML, Wolpert SM, Kwan E, Kaufman DM. The efficacy of tilted axial MRI of the CNS. Magnetic Resonance Imaging 1987; 5(6):421-430.
28. Wood ML, Silver M, Runge VM. Optimization of spoiler gradients in FLASH MRI. Magnetic Resonance Imaging 1987; 5:455-463.
29. Runge VM, Jacobson S, Wood ML, Kaufman DM, Adelman LS. MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA. Radiology 1988; 166(3):835-838.
30. Wood ML, Runge VM, Henkelman RM. Overcoming motion in abdominal MR imaging. American Journal of Roentgenology 1988; 150:513-522.
31. Wolpert SM, Osborne M, Anderson M, Runge VM. The bright pituitary gland -- a normal MR appearance in infancy. American Journal of Neuroradiology 1988; 9(1):1-3.
32. Runge VM. Gd-DTPA: An i.v. contrast agent for clinical MRI. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology 1988; 15(1):37-44.
33. Runge VM, Schaible TF, Goldstein HA, Wood ML, Haughton VM, Maravilla KR, Weinstein MA, Price AC, Wolpert SM, Kaufman DM. Gd DTPA - clinical efficacy. Radiographics 1988; 8(1):147-159.
34. Runge VM, Wood ML, Kaufman DM, Price AC. Gd DTPA. Future applications with advanced imaging techniques. Radiographics 1988; 8(1):161-179.
35. Runge VM, Wood ML, Kaufman DM, Silver MS. MR imaging section profile optimization: improved contrast and detection of lesions. Radiology 1988; 167:831-834.
36. Runge VM, Wood ML, Kaufman DM, Traill MR, Nelson KL. The straight and narrow path to good head and spine MRI. Radiographics 1988; 8(3):507-531.
37. Kwan ES, Wolpert SM, Scott RM, Runge V. MR evaluation of neurovascular lesions after endovascular occlusion with detachable balloons. American Journal of Neuroradiology 1988; 9(3):523-531.
38. Davis PL, Parker DL, Nelson JA, Gillen JS, Runge VM. Interactions of paramagnetic contrast agents and the spin echo pulse sequence. Investigative Radiology 1988; 23(5):381-388.
39. Wood ML, Runge VM. Application of image enhancement techniques to magnetic resonance imaging. Radiographics 1988; 8(4):771-784.
40. Carter BL, Runge VM: Imaging modalities for the study of the paranasal sinuses and nasopharynx. Otolaryngologic Clinics of North America. GE Valvassori and MF Mafee (Editors), W.B. Saunders, Philadelphia, 1988; 21(3):395-420.
41. Konstam MA, Aronovitz MJ, Runge VM, Kaufman DM, Brockway BA, Isner JM, Katzen NA, Dresdale AR, Diehl JT, Kaplan E, et al. Magnetic resonance imaging with gadolinium-DTPA for detecting cardiac transplant rejection in rats. Circulation 1988; 78(5):III-87-94.
42. Wolpert SM, Scott RM, Platenberg RC, Runge VM. The clinical significance of hindbrain herniation and deformity as shown on MR images of patients with Chiari II malformation. American Journal of Neuroradiology 1988; 9(1):1075-1078.
43. Canoso JJ, Liu N, Traill MR, Runge VM. Physiology of the retrocalcaneal bursa. Ann Rheum Dis 1988; 47(11):910-2.
44. Runge VM, Wood ML. Fast imaging and other motion artifact reduction schemes: a pictorial overview. Magnetic Resonance Imaging 1988; 6(5):595-608.
45. Runge VM, Wood ML, Kaufman DM, Nelson KL, Traill MR. FLASH: clinical three-dimensional magnetic resonance imaging. Radiographics 1988; 8(5):947-965.
46. Wood ML, Runge VM. Artifacts due to residual magnetization in three-dimensional magnetic resonance imaging. Medical Physics 1988; 15(6):825-831.
47. Robertson SW, Wolpert SM, Runge VM. Magnetic resonance imaging of middle cranial fossa arachnoid cysts: temporal lobe agenesis syndrome revisited. American Journal of Neuroradiology 1989; 10:1007-1010.
48. Runge VM, Carollo BR, Wolf CR, Nelson KL, Gelblum DY. Gd DTPA: a review of clinical indications in the central nervous system magnetic resonance imaging. Radiographics 1989; 9(5): 929-958.
49. Runge VM, Kaufman DM, Wood ML, Adelman LS, Jacobson S. Experimental trials with Gd(DO3A) -- a nonionic magnetic resonance contrast agent. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology 1989; 16(6):561-567.
50. Runge VM, Wood ML. Half-fourier MR imaging of CNS disease. American Journal of Neuroradiology 1990; 11:77-82.
51. Traill MR, Kaufman DM, Runge VM, McCarthy JC, Wood ML, Sterns DM, Harasimowicz PP. Anatomy of the proximal femur as seen with three-dimensional magnetic resonance imaging. J Arthroplasty 1989; 4(4):361-7.
52. Runge VM, Gelblum DY. The role of gadolinium-diethylenetriaminepentaacetic acid in evaluation of the central nervous system. Magnetic Resonance Quarterly 1990; 6(2):85-107.
53. Carollo BR, Runge VM, Price AC, Nelson KL, Wolf CR, Pacetti MI. The prospective evaluation of Gd DTPA in 225 consecutive cranial cases: adverse reactions and diagnostic value. Magnetic Resonance Imaging 1990; 8:381-393.
54. Runge VM, Gelblum DY, Pacetti ML, Carolan F, Heard G. Gd HP-DO3A in clinical MR imaging of the brain. Radiology 1990; 177:393-400.
55. Runge VM, Gelblum DY, Wood ML. 3-D imaging of the CNS. Neuroradiology 1990; 32:356-366.
56. Runge VM. Clinical applications of magnetic resonance contrast media in the head. Topics in Magnetic Resonance Imaging 1991; 3(2):19-40.
57. Runge VM, Gelblum DY. Future directions in magnetic resonance contrast media. Topics in Magnetic Resonance Imaging 1991; 3(2):85-98.
58. Runge VR, Gelblum DY, Jacobson S. Gd HP-DO3A -- experimental evaluation in brain and renal MR. Magnetic Resonance Imaging 1991; 9(1):79-87.
59. Runge VM, Bradley WG, Brant-Zawadzki MN, Carvlin MJ, DeSimone DN, Dean BL, Dillon WP, Drayer BP, Flanders AE, Harms SE, et al. Clinical safety and efficacy of gadoteridol: a study of 411 patients with suspected intracranial and spinal disease. Radiology 1991; 181:701-709.
60. Konstam MA, Aronovitz MJ, Runge VM, Isner JM, Foster EA, Kaufman DM, Diehl JT, Dresdale AR, Katzen NA, Kaplan E. Magnetic resonance imaging in ischemic injury after heart transplantation in rats. Journal of Heart and Lung Transplantation 1991; 10:750-756.
61. Runge VM. Magnetic resonance imaging contrast agents [editorial]. Current Opinion in Radiology 1992; 4(1):3-12.
62. Runge VM, Kirsch JE, Thomas GS, Mugler JP. Clinical comparison of three-dimensional MP-RAGE and FLASH techniques for MR imaging of the head. Journal of Magnetic Resonance Imaging 1991; 1(4):493-500.
63. Shih WJ, Hartman RS, McQuaide BH, Nugent E, Runge VM, Ryo UY. A large cystic lesion in the left posterior parietal region demonstrated by Tc-99m HMPAO brain SPECT imaging. Clin Nucl Med 1992; 17(1):54-55.
64. Runge VM, Dean B, Lee C, Carolan F, Heard G. Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. Journal of Magnetic Resonance Imaging 1991; 1:47-56.
65. Runge VM, Kirsch JE, Thomas GS. High dose applications of gadolinium chelates in magnetic resonance imaging. Magnetic Resonance in Medicine 1991; 22:358-363.
66. Lee C, Dean BL, Kirsch JE, Runge VM, Dempsey RJ, Howard RS, Pettigrew LC. Cerebral infarction: assessment of patterns using ultra-fast MR contrast imaging. American Journal of Neuroradiology 1992; 13:277-279.
67. Dean BL, Lee C, Kirsch JE, Runge VM, Dempsey RM, Pettigrew LC. Cerebral hemodynamics and cerebral blood volume: MR assessment using gadolinium contrast agents and T1-weighted turbo-FLASH imaging. American Journal of Neuroradiology 1992; 13:39-48.
68. Runge VM, Kirsch JE, Burke VJ, Price AC, Nelson KL, Thomas GS, Dean BL, Lee C. High-dose gadoteridol in MR imaging of intracranial neoplasms. Journal of Magnetic Resonance Imaging 1992; 2:9-18.
69. Runge VM, Bronen R, Davis KR. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine. Investigative Radiology 1992; 27(1):S22-S32.
70. Kaye EM, Alroy J, Raghavan SS, Schwarting GA, Adelman LS, Runge V, Gelblum D, Thalhammer JG, Zuniga G. Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatric Neurology 1992;8(4):255-261.
71. Runge VM, Kirsch JE, Lee C. Contrast-enhanced MR angiography. Journal of Magnetic Resonance Imaging 1993;3:233-239.
72. Runge VM, Kirsch JE, Wells JW, Woolfolk CE. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study. American Journal of Roentgenology 1993;160:593-600.
73. Hudgins PA, Elster AD, Runge VM, Kashanian FK, Goldstein HA. Efficacy and safety of gadopentetate dimeglumine in the evaluation of patients with a suspected tumor of the extracranial head and neck. Journal of Magnetic Resonance Imaging 1993;3:345-349.
74. Lee C, Dineen TE, Brack M, Kirsch JE, Runge VM. The mucopolysaccharidoses: characterization by cranial MR imaging. American Journal of Neuroradiology 1993;14:1285-1292.
75. Runge VM, Kirsch JE, Wells JW, Awh MH, Bittner DF, Woolfolk CE. Enhanced liver MR: contrast agents and imaging strategy. Critical Reviews in Diagnostic Imaging 1993;34:1-30.
76. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material. American Journal of Roentgenology 1994;162:431-435.
77. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Awh MH, Bittner DF. Magnetic resonance contrast agents in neuroimaging: new agents and applications. Neuroimaging Clinics of North America 1994;4(1):175-183.
78. Yuh WTC, Nguyen HD, Tali ET, Mayr NA, Fisher DJ, Atlas SW, Carvlin MC, Drayer BP, Pollei SR, Runge VM, Sze GK. Delineation of gliomas with various doses of MR contrast material. American Journal of Neuroradiology 1994;15:983-989.
79. Runge VM, Pels Rijcken TH, Davidoff A, Wells JW, Stark DD. Contrast-enhanced MR imaging of the liver. Journal of Magnetic Resonance Imaging 1994;4:281-289.
80. Runge VM, Kirsch JE, Woolfolk C, Brack MA, Garneau RA. Gadoteridol dose dependence in MR imaging of a liver abscess model. Journal of Magnetic Resonance Imaging 1994;4:343-350.
81. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Hilaire L, Woolfolk CE. Repeat cerebral blood volume assessment with first-pass MR imaging. Journal of Magnetic Resonance Imaging 1994;4:457-461.
82. Yuh WTC, Fisher DJ, Runge VM, Atlas SW, Harms SE, Maravilla KR, Mayr NA, Mollman JE, Price AC. Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. American Journal of Neuroradiology 1994;15:1037-1051 (June).
83. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. The question of dose for gadolinium chelates in magnetic resonance imaging. Investigative Radiology 1994;29(S2):154-156 (June).
84. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. Journal of Magnetic Resonance Imaging 1994;4(5):669-673 (September).
85. Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WTC, Runge VM, Morris MR, McLachlan SJ, Lufkin RB. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994;192:709-715 (September).
86. Mitchell DG, Saini S, Weinreb J, De Lange EE, Runge VM, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard and triple dose gadoteridol enhanced MR imaging. Radiology 1994;193:49-57 (October).
87. Runge VM, Wells JW, Williams NM. MR imaging of an experimental model of intracranial metastatic disease -- a study of lesion detectability. Investigative Radiology 1994;29(12):1050-1056.
88. Runge VM, Wells JW, Williams NM. Comparison of Gd Cy2DOTA, a new hepatobiliary agent, and Gd HP-DO3A, an extracellular agent, in normal liver and metastatic disease. Investigative Radiology 1995;30:123-130.
89. Runge VM, Wells JW, Kirsch JE. Magnetization transfer and high dose contrast in early brain infection on MR. Investigative Radiology 1995;30:135-143.
90. Nelson KL, Runge VM. Basic principles of MR contrast. Topics in Magnetic Resonance Imaging 1995;7(3):124-136.
91. Muroff LR, Runge VM. The use of MR contrast in neoplastic disease of the brain. Topics in Magnetic Resonance Imaging 1995;7(3):137-157.
92. Runge VM. The use of MR contrast in non-neoplastic disease of the brain. Topics in Magnetic Resonance Imaging 1995;7(3):158-167.
93. Jinkins JR, Runge VM. The use of MR contrast agents in the evaluation of disease of the spine. Topics in Magnetic Resonance Imaging 1995;7(3):168-180.
94. Runge VM, Wells JW. Update: safety, new applications, new MR agents. Topics in Magnetic Resonance Imaging 1995;7(3):181-195.
95. Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA, Jacobs PM. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
96. Petersein J, Saini S, Mitchell DG, Davis PL, Johnson CD, Kuhlman JE, Parisky YR, Runge VM, et al. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. AJR Am J Roentgenol 1995 Nov;165(5):1157-61.
97. Runge VM, Wells JW, Williams NM, Lee C, Timoney JF, Young AB. Detectability of early brain meningitis on MR. Investigative Radiology 1995;30(8):484-495.
98. Runge VM, Wells JW, Williams NM. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging. Investigative Radiology 1996;31(1):11-16.
99. Runge VM. Investigative Radiology and the World Wide Web. Investigative Radiology 1996;31(4):183 (editorial).
100. Runge VM, Wells JW, Williams NM, Timoney JF, Lee C. The use of gadolinium BOPTA on magnetic resonance imaging in brain infection. Investigative Radiology 1996;31(5):294-299.
101. Runge VM, Wells JW. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with MRI at 1.5 tesla. Investigative Radiology 1996;31(7):395-400.
102. Runge VM, Wells JW. Comparison of MR hepatobiliary gadolinium chelates, including BOPTA, EOB-DTPA, Cy2DOTA and 2,5-BPA-DO3A. Academic Radiology 1996;3:S455-S457.
103. Runge VM, Wells JW, Williams NM. Early dynamic MR imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection. Investigative Radiology 1996;31(8):472-478.
104. Runge VM, Wells JW, Williams NM. Hepatic abscesses: magnetic resonance imaging findings using gadolinium BOPTA. Investigative Radiology 1996;31(12):781-788.
105. Runge VM, Muroff LR, Wells JW. Principles of contrast enhancement in the evaluation of brain diseases: an overview. Journal of Magnetic Resonance Imaging 1997;7:5-13.
106. Runge VM, Wells JW, Baldwin SA, Scheff SW, Blades DA. Evaluation of the temporal evolution of acute spinal cord injury. Investigative Radiology 1997;32(2):105-110.
107. Runge VM, Wells JW, Williams NM. Renal metastasis: detection and characterization on enhanced magnetic resonance imaging using an animal model. Investigative Radiology 1997;32(4):212-127.
108. Runge VM. Liver MRI with contrast enhancement. Critical Reviews in Diagnostic Imaging 1997;38(3):207-230.
109. Runge VM, Lee C, Williams NM. Detectability of small liver metastases with gadolinium BOPTA. Investigative Radiology 1997;32(9):557-565.
110. Runge VM, Lee C, Iten AL, Williams NM. Contrast enhanced magnetic resonance imaging in a spinal epidural tumor model. Investigative Radiology 1997;32(10):589-595.
111. Runge VM, Timoney JF, Williams NM. Magnetic resonance imaging of experimental pyelonephritis in rabbits. Investigative Radiology 1997;32(11):696-704.
112. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. European Radiology 1997;7(suppl 5):S243-S245.
113. Runge VM, Williams NM. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis. Investigative Radiology 1998;33(1):45-50.
114. Runge VM, Williams NM. Investigation of MR contrast media utility with the VX-2 tumor model. Academic Radiology 1998;5(suppl 1):S34-S36.
115. Runge VM, Williams NM, Lee C, Timoney JF. Magnetic resonance imaging in a spinal abscess model. Investigative Radiology 1998;33(4):246-255.
116. Runge VM. Evaluation of standard and high dose contrast enhanced breath-hold liver MR for visualization of metastatic disease in an animal model. Investigative Radiology 1998;33(5):263-267.
117. Runge VM. A comparison of two MR hepatobiliary gadolinium chelates, Gd-BOPTA and Gd-EOB-DTPA. Journal of Computer Assisted Tomography 1998;22(July/August):643-650.
118. Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK, Morris M, Lucas M. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. Journal of Magnetic Resonance Imaging 1999;9:291-294.
119. Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF,…, Runge VM, et al. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal of Magnetic Resonance Imaging 1999;10:15-24.
120. Runge VM, Knopp MV. Changes in the approval process for contrast media. Journal of Magnetic Resonance Imaging 1999;10(3):485-488.
121. Runge VM. Off-label use and reimbursement of contrast media in MR. Journal of Magnetic Resonance Imaging 1999;10(3):489-495.
122. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N. MR imaging of tumor microcirculation: promise for the new millennium. Journal of Magnetic Resonance Imaging 1999;10(6)903-7.
123. Runge VM. Contrast media research. Investigative Radiology 1999;34(12):785-90.
124. Marinelli ER, Neubeck R, Song B, Wagler T, Ranganathan RS, Sukumaran K Wedeking PW, Nunn A, Runge VM, Tweedle MF. Synthesis, characterization and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents. Investigative Radiology 2000;35(1):8-24.
125. Runge VM, Kenney CM. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging. Journal of Magnetic Resonance Imaging 2000; 11(6):655-64. Reprinted in Applied Radiology 2003; April (supplement): 137-146.
126. Runge VM. Safety of approved MR contrast media for intravenous injection. Journal of Magnetic Resonance Imaging 2000;12:205-213 (August).
127. Shih WJ, Runge VM, Mitchell BL, Pulmano C. Comparison of bone SPECT, MRI, and CT in the demonstration of vertebral metastases from bronchogenic carcinoma: an autopsy documented case. Clinical Nuclear Medicine August 2000; 25:647-9.
128. Saini S, Sharma R, Baron RL, Turner DA, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clinical Radiology 2000;55(9):690-5.
129. Runge VM, Armstrong MR, Barr RG, et al. A Clinical Comparison of the Safety and Efficacy of MultiHance (Gadobenate Dimeglumine) and Omniscan (Gadodiamide) in Magnetic Resonance Imaging in Patients with Central Nervous System Pathology. Investigative Radiology 2001;36(2):65-71. Reprinted in Applied Radiology 2003; April (supplement): 71-77.
130. Runge VM. A review of contrast media research in 1999 - 2000. Investigative Radiology 2001;36(2):123-130.
131. Knopp MV, Lodemann M, Kage U, Runge VM. Use of MR contrast agents outside of their labeled indication. Radiologe 2001;41:296-302.
132. Essig M, Hartmann M, Lodemann KP, et al. [Comparison of contrast behavior of gadobenate-dimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study]. Radiologe 2001;41:1063-1071. Reprinted in Applied Radiology 2003; April (supplement): 92-100.
133. Runge, VM. Allergic reactions to gadolinium chelates. American Journal of Roentgenology 2001;177:944 (letter to Editor).
134. Runge VM. Editorial. Topics in Magnetic Resonance Imaging 2001;12(4):219.
135. Runge VM, Muroff LR, Jinkins JR. Central Nervous System: Review of Clinical Use of Contrast Media. Topics in Magnetic Resonance Imaging 2001;12(4):231-263.
136. Runge VM. Safety of Magnetic Resonance Contrast Media. Topics in Magnetic Resonance Imaging 2001;12(4):309-314.
137. Runge VM. Trends in Contrast Media Research (Editorial). Investigative Radiology 2001;36(12):688-691.
138. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Investigative Radiology 2002;37(5):269-280.
139. Runge VM, Dickey KM, Williams NM, Peng X. Local Tissue Toxicity in Response to Extravascular Extravasation of Magnetic Resonance Contrast Media. Investigative Radiology 2002;37(7):393-8.
140. Marinelli ER, Neubeck R, Song B, Wagler T, Ranganathan RS, Sukumaran K Wedeking P, Nunn A, Runge VM, Tweedle MF. Synthesis and evaluation of macrocyclic gadolinium chelates as hepatospecific MRI agents. Academic Radiology 2002:9(supplement 1):251-4.
141. Runge VM. Contrast Media Research (Editorial). Investigative Radiology 2002;37(12):643-6.
142. Desai NK, Runge VM, Crisp DE, Crisp MB, Naul LG. Magnetic resonance imaging of the brain in glutaric acidemia type I: a review of the literature and a report of four new cases with attention to the basal ganglia and imaging technique. Investigative Radiology 2003:38(8):489-96.
143. Runge VM. Editorial. Topics in Magnetic Resonance Imaging 2003;14(5):359 (October).
144. Desai NK, Runge VM. Contrast Use at Low Field: a Review. Topics in Magnetic Resonance Imaging 2003;14(5):360-4 (October).
145. Kirchin MA, Runge VM. Contrast Agents for Magnetic Resonance Imaging: Safety Update. Topics in Magnetic Resonance Imaging 2003;14(5):426-35 (October).
146. Runge VM. Magnetic Resonance Research (Editorial). Investigative Radiology 2003;38(12):802-5.
147. Knopp MV, Runge VM, Essig M, et al. Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine. Radiology 2004;230:55-64.
148. Runge VM. Advances in Magnetic Resonance (Editorial). Investigative Radiology 2004;39(12):713-716.
149. Biswas J, Nelson B, Runge VM, Wintersperger BJ, Baumann SS, Jackson CB, Patel T. Brain Tumor Enhancement in MR Imaging: Comparison of Signal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) at 1.5 versus 3 Tesla. Investigative Radiology 2005;40(12):792-797.
150. Runge VM. Advances in Magnetic Resonance 2005 (Review). Investigative Radiology 2005;40(12):798-802.
151. Runge VM, Kuehl TJ, Jackson CB, Estrada EA. Subchronic Toxicity of the Gadolinium Chelates. Academic Radiology May 2005;12(Supplement 1):S6-9.
152. Runge VM, Case RS, Sonnier HL. Advances in Clinical 3-Tesla Neuroimaging. Investigative Radiology 2005;41(2):63-67.
153. Herborn CU, Watkins DM, Runge VM, Gendron JM, Montgomery ML, Naul LG. Renal arteries: comparison of steady-state free precession MR angiography and contrast-enhanced MR angiography. Radiology 2006;239:263-268.
154. Runge VM, Patel MC, Baumann SS, Simonetta AB, Ponzo JA, et al. T1-weighted Imaging of the Brain at 3 Tesla Using a 2D Spoiled Gradient Echo Technique. Investigative Radiology 2006;41(2):68-75.
155. Runge VM, Biswas J, Wintersperger BJ, Baumann SS, Jackson CB, Herborn CU, Patel T. The Efficacy of Gadobenate Dimeglumine (Gd-BOPTA) at 3 Tesla in Brain MR Imaging: Comparison to 1.5 Tesla and a Standard Gadolinium Chelate Using a Rat Brain Tumor Model. Investigative Radiology 2006;41(3):244-248.
156. Wintersperger BJ, Runge VM, Biswas J, Nelson CB, Stemmer A, Simonetta AB, Reiser MF, Naul LG, Schoenberg SS. Brain MR Imaging at 3 Tesla using BLADE Compared with Standard Rectilinear Data Sampling. Investigative Radiology 2006;41(7):586-592.
157. Nowinski WL, Qian G, Kirgaval Nagaraja BP, Thirunavuukarasuu A, Hu Q, Ivanov N, Parimal AS, Runge VM, Beauchamp NJ. Analysis of Ischemic Stroke MR Images by Means of Brain Atlases of Anatomy and Blood Supply Territories. Acad Radiol 2006;13:1025-1034.
158. Maravilla KR, Maldjian JA, Schmalfuss IM, Kuhn MJ, Bowen BC, Wippold FJ, Runge VM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389-400.
159. Kramer LA, Gendron JM, Pierce LM, Runge VM, Shull BL, Kuehl TJ. Magnetic resonance imaging of the levator ani in the squirrel monkey: A comparison of muscle volume between a cohort with pelvic organ prolapse and matched normals. Am J Obstet Gynecol 2006;194:1467-1471.
160. Runge VM. Advances in Magnetic Resonance (2006). Investigative Radiology 2006;41(12):904-9.
161. Wintersperger BJ, Sincleair S, Runge VM, Dietrich O, Huber A, Reiser MF, Schoenberg SO. Dual breath-hold magnetic resonance cine evaluation of global and regional cardiac function. European Radiology 2007;17(1):73-80.
162. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42(2):139-145
163. Kuhn MJ, Picozzi P, Maldjian JA, Schmalfuss IM, Maravilla KR, Bowen BC, Wippold FJ, Runge VM, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. Journal of Neurosurgery 2007;106:557-566.
164. Herborn CU, Watkins DM, Baumann S, Robert P, Corot C, Runge VM. Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T. Investigative Radiology 2007;42:622-628.
165. Runge VM. Advances in Magnetic Resonance (2007). Investigative Radiology 2007;42(12):862-7.
166. Herborn CU, Runge VM, Watkins DM, Gendron JM, Naul LG. MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T. AJR 2008; 190:173–177.
167. Runge VM. Notes on “Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent”. Centennial Article Commentary. American Journal of Roentgenology (AJR) 2008; 190:1433-1434.
168. Sandner TA, Houck P, Runge VM, Sincleair S, Huber AM, Theisen D, Reiser MF, Wintersperger BJ. Accuracy of accelerated cine MR imaging at 3 Tesla in longitudinal follow-up of cardiac function. Eur Radiol 2008;18(10):2095-101.
169. Fries P, Runge VM, Kirchin MA, Watkins DM, Buecker A, Schneider G. Magnetic Resonance Imaging of the Spine at 3 Tesla. Seminars in Musculoskeletal Radiology 2008;3(12):183-280.
170. Runge VM. Advances in Magnetic Resonance (2008). Investigative Radiology 2008;43(12):893-8.
171. Nowinski WL, Volkau I, Marchenko Y, Thirunavuukarasuu A, Ng TT, Runge VM. A 3D model of human cerebrovasculature derived from 3T magnetic resonance angiography. Neuroinformatics 2009;7:23-36.
172. Nowinski WL, Thirunavuukarasuu A, Volkau I, Marchenko Y, Aminah B, Gelas A, Huang S, Lee LC, Liu J, Ng TT, Nowinska NG, Qian GY, Puspitasari F, Runge VM. A new presentation and exploration of human cerebral vasculature correlated with surface and sectional neuroanatomy. Anat Sci Educ 2009;2(1):24-33.
173. Fries P, Runge VM, Buecker A, Schuerholz H, Reith W, Baumann SS, Robert P, Jackson C, Lanz T, Schneider G. Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla - Intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular Gd-Chelate in a rat brain tumor model. Invest Radiol 2009;44:200-206.
174. Wintersperger BJ, Runge VM, Tweedle MF, Jackson CB, Reiser MF. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol 2009;44:89-94.
175. Attenberger UI, Runge VM, Williams KD, Stemmer A, Michaely HJ, Reiser MF, Schoenberg SO, Wintersperger BJ. T1-weighted Brain Imaging with a 32-Channel Coil at 3T Using TurboFLASH BLADE Compared with Standard Cartesian k-Space Sampling. Invest Radiol 2009 44(3):177-183.
176. Runge, VM. Gadolinium and Nephrogenic Systemic Fibrosis. AJR Am J Roentgenol 2009 192:W195-196.
177. Attenberger UI, Runge VM, Jackson CB, Baumann S, Birkemeier K, Michaely HJ, Reiser MF, Schoenberg SO, Wintersperger BJ. Comparative Evaluation of Lesion Enhancement using 1 M Gadobutrol vs Two Conventional Gadolinium Chelates, all at a Dose of 0.1 mmol/kg, in a Rat Brain Tumor Model at 3 T. Invest Radiol 2009 44(5):251-6.
178. Fries P, Runge VM, Kirchin MA, Stemmer A, Naul LG, Williams KD, Buecker A, Schneider G. Diffusion Weighted Imaging in Patients with Acute Brain Ischemia at 3 T – Current Possibilities and Future Perspectives Comparing Conventional Echoplanar DWI and FSE DWI Sequences Using BLADE (PROPELLER). Invest Radiol 2009 44(6):351-9.
179. Attenberger UI, Runge VM, Stemmer A, et al. Diffusion Weighted Imaging: A Comprehensive Evaluation of a Fast Spin Echo DWI Sequence With BLADE (PROPELLER) k-Space Sampling at 3 T, Using a 32-Channel Head Coil in Acute Brain Ischemia. Invest Radiol 2009 44(10):656-661.
180. Runge VM. Advances in Magnetic Resonance (2009). Invest Radiol 2009 44(12):808–812.
181. Nowinski WL, Thirunavuukarasuu A, Volkau I, Marchenko Y, Aminah B, Puspitasari F, Runge, VM. A three-dimensional interactive atlas of cerebral arterial variants. Neuroinformatics 2009 7:255-264.
182. Morelli JN, Runge VM, Feiweier T, Kirsch JE, Williams KW, Attenberger UI. Evaluation of a Modified Stejskal-Tanner Diffusion Encoding Scheme, Permitting a Marked Reduction in TE, in Diffusion-Weighted Imaging of Stroke Patients at 3 T. Invest Radiol 2010 44(1):29-35.
183. Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ. Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine. AJR Am J Roentgenol 2010; 194:1337–1342.
184. Attenberger UI, Runge VM, Morelli JN, Williams J, Jackson C, Michaely HJ. Evaluation of Gadobutrol, a Macrocyclic, Non-ionic Gd Chelate in a Brain Glioma Model: Comparison with Gadoterate Meglumine and Gadopentetate Dimeglumine at 1.5 T, Combined with an Assessment of Field Strength Dependence, Specifically 1.5 vs 3 T. J Magn Reson Imaging 2010;31:549-555.
185. Giesel FL, Runge V, Kirchin M, et al. Three-dimensional multiphase time-resolved low-dose contrast-enhanced magnetic resonance angiography using TWIST on a 32-channel coil at 3 T: a quantitative and qualitative comparison of a conventional gadolinium chelate with a high-relaxivity agent. J Comput Assist Tomogr 2010;34:678-683.
186. Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI. Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T. Invest Radiol 2010 45(12):810-818.
187. Nowinski WL, Chua BC, Volkau I, Puspitasari R, Marchenko Y, Runge VM, Knopp MV. Simulation and assessment of cerebrovascular damage in deep brain stimulation using a stereotactic atlas of vasculature and structure derived from multiple 3- and 7-tesla scans. J Neurosurg 2010;113:1234-1241.
188. Runge VM. Advances in Diagnostic Radiology. Invest Radiol 2010 45(12):823-826.
189. Morelli JN, Runge VM, Williams JM, Beissner RS, Tweedle M. Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model. Invest Radiol 2011;46:169-177.
190. Kramer H, Runge VM, Morelli JN, et al. Magnetic resonance angiography of the carotid arteries: comparison of unenhanced and contrast enhanced techniques. Eur Radiol 2011 Aug;21(8):1667-76.
191. Bracken JN, Reyes M, Gendron JM, Pierce LM, Runge VM, Kuehl TJ. Alterations in pelvic floor muscles and pelvic organ support by pregnancy and vaginal delivery in squirrel monkeys. Int Urogynecol J 2011; 22:1109-1116.
192. Morelli JN, Runge VM, Ai F, et al. An image-based approach to understanding the physics of MR artifacts. Radiographics 2011 May-Jun;31(3):849-66.
193. Runge VM, Ai T, Hao D, Hu X. The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance. Invest Radiol 2011; 46:807–816.
194. Ai T, Padua A, Goerner F, Nittka M, Gugala Z, Jadhav S, Trelles M, Johnson RF, Lindsey RW, Li X, Runge VM. SEMAC-VAT and MSVAT-SPACE Sequence Strategies for Metal Artifact Reduction in 1.5 T Magnetic Resonance Imaging. Invest Radiol 2012;47:267-76.
195. Morelli JN, Runge VM, Ai F, et al. Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography. Invest Radiol 2012; 47:376-82.
196. Morelli JN, Ai F, Runge VM, et al. Time-resolved MR angiography of renal artery stenosis in a swine model at 3 Tesla using gadobutrol with digital subtraction angiography correlation. J Magn Reson Imaging 2012; 36(3):704-713.
197. Wuesten O, Morelli JN, Miller MW, Tuzun E, Lenox MW, Fossum TW, Trelles M, Cotes C, Krombach GA, Runge VM. MR angiography of carotid artery aneurysms in a porcine model at 3 tesla: Comparison of two different macrocyclic gadolinium chelates and of dynamic and conventional techniques. J Magn Reson Imaging 2012; 36(5):1203-12.
198. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012; 36(5):1060-71.
199. Ai T, Morelli JN, Hu X, Hao D, Goerner FL, Ager B, Runge VM. A Historical Overview of Magnetic Resonance Imaging, Focusing on Technological Innovations. Invest Radiol 2012;47:725-741.
200. Ai T, Goerner FL, Patel N, Trelles M, Wu G, Li X, Runge VM. Contrast Dose, Temporal Footprint, and Spatial Resolution Tradeoffs in Dynamic Contrast Enhanced MRA Performed in a Porcine Model of a Carotid Aneurysm. J Comput Assist Tomogr 2013;37(1):105-10.
201. Reichert M, Morelli JN, Runge VM, et al. Contrast-enhanced 3-dimensional SPACE versus MP-RAGE for the detection of brain metastases: considerations with a 32-channel head coil. Invest Radiol 2013;48(1):55-60.
202. Morelli JN, Gerdes CM, Schmitt P, Ai T, Saettele MR, Runge VM, et al. Technical considerations in MR angiography: an image-based guide. J Magn Reson Imaging 2013;37(6):1326-41.
203. Morelli J, Porter D, Ai F, Gerdes C, Saettele M, Feiweier T, et al. Clinical evaluation of single-shot and readout-segmented diffusion-weighted imaging in stroke patients at 3 T. Acta Radiol 2013;54(3):299-306.
204. Runge VM. Current technological advances in magnetic resonance with critical impact for clinical diagnosis and therapy. Invest Radiol 2013;48(12):869-77.
205. Finkenstaedt T, Morsbach F, Calcagni M, Vich M, Pfirrmann CW, Alkadhi H, Runge VM, Andreisek G, Guggenberger R. Metallic artifacts from internal scaphoid fracture fixation screws: comparison between C-arm flat-panel, cone-beam, and multidetector computed tomography. Invest Radiol 2014;49(8):532-9.
206. Goetschi S, Froehlich JM, Chuck NC, Curcio R, Runge VM, Andreisek G, et al. The protein and contrast agent-specific influence of pathological plasma-protein concentration levels on contrast-enhanced magnetic resonance imaging. Invest Radiol 2014;49(9):608-19.
207. Ai T, Yu K, Gao L, Zhang P, Goerner F, Runge VM, Li X. Diffusion tensor imaging in evaluation of thigh muscles in patients with polymyositis and dermatomyositis. Br J Radiol 2014;87(1043):20140261.
208. Daubler BF, Kamli A, Runge VM. Readout-Segmented Diffusion-Weighted Imaging in a Critical Anatomic Area - Diagnosing Posterior Ischemic Optic Neuropathy (PION). Rofo 2014;186(12):1151-2.
209. Zhang P, Yu K, Guo R, Shah S, Morelli JN, Runge VM, Li X. Ankylosing spondylitis: correlations between clinical and MRI indices of sacroiliitis activity. Clin Radiol 2015;70(1):62-6.
210. Runge VM, Paulo MMH, Andreisek G, Valavanis A, Alkadhi H. Recent Technological Advances in CT, and the Clinical Impact Therein. Invest Radiol 2015;50(2):119-27.
211. Shen Y, Goerner FL, Snyder C, Morelli JN, Hao D, Hu D, Li X, Runge VM. T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3 and 7 Tesla. Invest Radiol 2015;50(5):330-8.
212. Reichert M, Ai T, Morelli J, Nittka M, Attenberger U, Runge VM. Metal Artifact Reduction in MR Imaging at Both 1.5T and 3T Using Slice-Encoding for Metal Artifact Correction and View-Angle Tilting. BJR 2015;88(1048):20140601.
213. Filli L, Piccirelli M, Kenkel D, Guggenberger R, Andreisek G, Beck T, Runge VM, Boss A. Simultaneous Multislice Echo Planar Imaging With Blipped Controlled Aliasing in Parallel Imaging Results in Higher Acceleration: A Promising Technique for Accelerated Diffusion Tensor Imaging of Skeletal Muscle. Invest Radiol 2015;50(7):456-63.
214. Runge VM. Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. Invest Radiol 2015;50(8):481-2.
215. Runge VM. Fifty Years of the Best of Investigative Radiology. Invest Radiol 2015;50(9):549-50.
216. Runge VM, Aoki S, Bradley WG, Chang KH, Essig M, Ma L, Ross JS, Valavanis A. MRI and CT of the Brain, 50 Years of Innovation, With a Focus on the Future. Invest Radiol 2015;50(9):551-6.
217. Runge VM. Macrocyclic Versus Linear Gadolinium Chelates. Invest Radiol 2015;50(12):811.
218. Higashigaito K, Angst F, Runge VM, Alkadhi H, Donati OF. Metal Artifact Reduction in Pelvic Computed Tomography With Hip Prostheses: Comparison of Virtual Monoenergetic Extrapolations From Dual-Energy Computed Tomography and an Iterative Metal Artifact Reduction Algorithm in a Phantom Study. Invest Radiol. 2015;50(12):828-34.
219. Filli L, Piccirelli M, Kenkel D, Boss A, Manoliu A, Andreisek G, Bhat H, Runge VM, Guggenberger R. Accelerated magnetic resonance diffusion tensor imaging of the median nerve using simultaneous multi-slice echo planar imaging with blipped CAIPIRINHA. Eur Radiol. 2016;26(6):1921-8.
220. Filli L, Ghafoor S, Kenkel D, Liu W, Weiland E, Andreisek G, Frauenfelder T, Runge VM, Boss A. Simultaneous multi-slice readout-segmented echo planar imaging for accelerated diffusion-weighted imaging of the breast. Eur J Radiol. 2016;85(1):274-8.
221. Kenkel D, Wurnig MC, Filli L, Ulbrich E, Runge VM, et al. Whole-Body Diffusion Imaging Applying Simultaneous Multi-Slice Excitation. Rofo. 2016;188(4):381-8.
222. Runge VM. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus. Invest Radiol. 2016;51(5):273-9.
223. Zhang P, Yu KH, Guo RM, Ran J, Liu Y, Morelli J, Runge V, Li X. Comparing the diagnostic utility of sacroiliac spectral CT and MRI in axial spondyloarthritis. Br J Radiol. 2016;89(1059):20150196.
224. Zhang P, Yu KH, Guo RM, Ran J, Liu Y, Morelli J, Runge V, Li X. A novel diagnostic method (spectral computed tomography of sacroiliac joints) for axial spondyloarthritis. J Formos Med Assoc. 2016;115(8):658-64.
225. Schawkat K, Kuhn W, Inderbitzin D, Gloor B, Heverhagen JT, Runge VM, Christe A. Diagnostic Value and Interreader Agreement of the Pancreaticolienal Gap in Pancreatic Cancer on MDCT. PLoS One. 2016;11(11): e0166003.
226. Runge VM, Richter JK, Heverhagen JT. Speed in clinical magnetic resonance. Invest Radiol. 2017;52(1):1-17.
227. Runge VM. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Invest Radiol. 2017;52(6):317-23.
228. Filli L, Jud L, Luechinger R, Nanz D, Andreisek G, Runge VM, Kozerke S, Farshad-Amacker NA. Material-Dependent Implant Artifact Reduction Using SEMAC-VAT and MAVRIC - A Prospective MRI Phantom Study. Invest Radiol. 2017;52(6):381-7.
229. Schawkat K, Ith M, Christe A, Kuhn W, Chittazhathu Y, Bains L, Runge VM, Heverhagen JT. Dynamic non-invasive ASL perfusion imaging of a normal pancreas with secretin augmented MR imaging. Eur Radiol. 2018;28(6):2389-96.
230. Runge VM, Heverhagen JT. Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance. Invest Radiol. 2018;53:381-389.
231. Shen Y, Goerner FL, Heverhagen JT, Snyder C, Hu D, Li X, Runge VM. In vitro T2 relaxivities of the Gd-based contrast agents (GBCAs) in human blood at 1.5 and 3T. Acta Radiologica (Epub Date 2018/09/13).
232. Runge VM. Dechelation - Consequences and Safety Concerns with the Linear Gadolinium Based MR Contrast Media, In View of Recent Health Care Rulings by the EMA (Europe), FDA (USA), and PMDA (Japan). Invest Radiol. 2018;53:571-8.
233. Runge VM, Richter JK, Heverhagen JT. Motion in MR - New Paradigms for Improved Clinical Diagnosis. Invest Radiol 2019;54:(Epub Date 2019/04/05).
234. Bower DV, Richter JK, von Tengg-Kobligk H, Heverhagen JT, Runge VM. Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases with Reduced Kinetic Stability of the Agent. Invest Radiol 2019;54:(in press).
235. Runge VM. The clinical safety of gadoteridol, representative of the macrocyclic class of gadolinium-based contrast agents. J Magn Reson Imaging 2019 - First published: 15 October 2019, https://doi.org/10.1002/jmri.26957, 2020;51:869-70.
236. Runge VM, Heverhagen JT. Advocating the Development of Next-Generation, Advanced-Design Low-Field Magnetic Resonance Systems. Invest Radiol 2020;55:747-753.
237. Runge VM, Heverhagen JT. Scientific Advances, Investigative Radiology 2020 (and Beyond). Invest Radiol 2021;56:271-273.
238. Runge VM, Heverhagen JT. The Clinical Utility of Magnetic Resonance Imaging According to Field Strength, Specifically Addressing the Breadth of Current State-of-the-Art Systems, Which Include 0.55 T, 1.5 T, 3 T, and 7 T. Invest Radiol 2022;57:1-12.
239. Fritz J, Runge VM. Scientific Advances and Technical Innovations in Musculoskeletal Radiology. Invest Radiol. 2023;58(1):1-2.
240. Alkadhi H, Runge V. The Future Arrived: Photon-Counting Detector CT. Invest Radiol. 2023;58(7):439-40.
241. Runge VM, Heverhagen JT. A New Era in Magnetic Resonance Contrast Media. Invest Radiol. 2024;59(2):105-7.